ImageneBio, Inc.
IMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001835579
In the last 90 days, ImageneBio, Inc. insiders filed 0 open-market purchases and 1 sale; 35 institutions reported holding it in 13F filings for Q2 2026, worth $36.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by ImageneBio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $17.3K in total
- Insiders trading
- 1
- Net value
- −$17.3K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for ImageneBio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Yarema Kristin | Chief Executive Officer | 493,705 | Aug 17, 2026 | 3 |
| Grant-Huerta Yanina | Chief Financial Officer | 104,000 | Aug 17, 2026 | 1 |
| Lally Robert B | Principal Accounting Officer | 55,582 | Jul 20, 2026 | 1 |
| Slattery Joseph P | Director | 16,000 | Jun 18, 2026 | 3 |
| Stampacchia Otello | Director | 454,982Indirect | Jun 18, 2026 | 1 |
| Wang Jonathan Jian | Director | 971,173Indirect | Jun 18, 2026 | 2 |
| Bonita David P | Director | 287,885Indirect | Jun 18, 2026 | 2 |
| OrbiMed Advisors LLC | Director | 287,885Indirect | Apr 16, 2026 | 1 |
| OrbiMed Capital GP VI LLC | Director | 287,885Indirect | Apr 16, 2026 | 1 |
| OrbiMed Genesis GP LLC | Director | 287,885Indirect | Apr 16, 2026 | 1 |
| Butler Erin | Principal Accounting Officer | 25,551 | Jan 2, 2026 | 1 |
| Wang Stephen Hui | Director | 12,535Indirect | Dec 22, 2025 | 2 |
| Lu Yufang | Chief Medical Officer | – | Aug 7, 2025 | 0 |
| Marango Jotin | Chief Financial Officer | 11,146 | Jul 29, 2025 | 0 |
| Formela Jean Francois | Director | 1,241,935Indirect | Jun 10, 2024 | 0 |
| Hughes Owen | Director | – | Jun 10, 2024 | 0 |
| Dukes Iain D. | Director | – | Jun 10, 2024 | 0 |
| Wooster Richard | Director | – | Jun 10, 2024 | 0 |
| Koehler Maria | Director | – | Jun 10, 2024 | 0 |
| Germa Caroline | Chief Medical Officer | – | Mar 5, 2024 | 0 |
| Ecsedy Jeffrey | Chief Development Officer | – | Feb 2, 2024 | 0 |
| Manfredi Mark | President & CEO | – | Feb 2, 2024 | 0 |
| Santillana Sergio L. | Chief Medical Officer | – | Jan 5, 2023 | 0 |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | 44,475 | Jan 5, 2023 | 0 |
| Renaud Ronald C JR | Director | – | Jun 13, 2022 | 0 |
| Tessier Maude | Chief Business Officer | 100,578 | Feb 4, 2022 | 0 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 1,241,935 | Dec 14, 2021 | 0 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 1,241,935 | Dec 14, 2021 | 0 |
| Atlas Venture Associates Opportunity I, L.P. | 10% Owner | 1,241,935 | Dec 14, 2021 | 0 |
| Atlas Venture Associates Opportunity I, LLC | 10% Owner | 1,241,935 | Dec 14, 2021 | 0 |
| Atlas Venture Associates XI, LLC | 10% Owner | 1,241,935 | Dec 14, 2021 | 0 |
| Atlas Venture Associates XI, L.P. | 10% Owner | 1,241,935 | Dec 14, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 (view filing)9:47 PM ET | Jul 16-17 | 4 days | Lally Robert BPrincipal Accounting Officer | SSale | −3.20K | $5.42 | −$17.3K | −5.4%55.6K after | 2 lots |
| Apr 16, 2026 (view filing)7:23 PM ET | Apr 14 | 2 days | OrbiMed Advisors LLC and 2 othersDirector | PPurchase | +721.3K | – | – | –384.7K after | Derivative2 lotsDuplicate filing |
| Apr 16, 2026 (view filing) | Apr 14 | 2 days | Bonita David PDirector | PPurchase | +721.3K | – | – | –384.7K after | Derivative2 lots |
| Dec 29, 2025 (view filing) | Dec 24 | 5 days | Slattery Joseph PDirector | PPurchase | +16.0K | $5.99 | +$95.8K | New position16.0K after | |
| Jul 30, 2025 (view filing) | Jul 25 | 5 daysLate | Bonita David PDirector | PPurchase | +83.6K | $29.90 | +$2.50M | +40.9%287.9K after | |
| Jul 30, 2025 (view filing) | Jul 25 | 5 daysLate | Stampacchia OtelloDirector | PPurchase | +267.6K | $29.90 | +$8.00M | +142.8%455.0K after | |
| Jun 24, 2022 (view filing)5:39 PM ET | Jun 22-24 | 2 days | OrbiMed Advisors LLC and 2 othersDirector | PPurchase | −252.2K | $4.47 | −$1.13M | −10.7%2.10M after | 4 lotsDuplicate filing |
| Jun 24, 2022 (view filing) | Jun 22-24 | 2 days | Bonita David PDirector | PPurchase | −252.2K | $4.47 | −$1.13M | −10.7%2.10M after | 4 lots |
| Jan 12, 2022 (view filing) | Jan 10-11 | 2 days | Zhang Xiaoyan MichelleChief Scientific Officer | SSale | −1.00K | $12.00 | −$12.0K | −2.2%44.5K after | 2 lots |
| Dec 14, 2021 (view filing)8:27 PM ET | Mar 30 | 259 daysLate | Atlas Venture Fund XI, L.P. and 5 others10% Owner | PPurchase | +125.0K | $16.00 | +$2.00M | +16.7%874.6K after | Duplicate filing |
| Dec 14, 2021 (view filing)8:27 PM ET | Dec 10-14 | 4 days | Atlas Venture Fund XI, L.P. and 5 others10% Owner | SSale | −26.3K | $14.67 | −$385.6K | −2.1%1.24M after | 3 lotsDuplicate filing |
| Dec 14, 2021 (view filing) | Mar 30 | 259 daysLate | Formela Jean FrancoisDirector | PPurchase | +125.0K | $16.00 | +$2.00M | +16.7%874.6K after | |
| Dec 14, 2021 (view filing) | Dec 10-14 | 4 days | Formela Jean FrancoisDirector | SSale | −26.3K | $14.67 | −$385.6K | −2.1%1.24M after | 3 lots |
| Dec 14, 2021 (view filing) | Dec 10 | 4 days | Zhang Xiaoyan MichelleChief Scientific Officer | SSale | −1.00K | $14.76 | −$14.8K | −2.2%44.5K after |